These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 30054596)

  • 1. Reply to 'DNA methylation haplotypes as cancer markers'.
    Diep D; Zhang K
    Nat Genet; 2018 Aug; 50(8):1063-1066. PubMed ID: 30054596
    [No Abstract]   [Full Text] [Related]  

  • 2. DNA methylation haplotypes as cancer markers.
    Seoighe C; Tosh NJ; Greally JM
    Nat Genet; 2018 Aug; 50(8):1062-1063. PubMed ID: 30054597
    [No Abstract]   [Full Text] [Related]  

  • 3. General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells.
    Gebhard C; Benner C; Ehrich M; Schwarzfischer L; Schilling E; Klug M; Dietmaier W; Thiede C; Holler E; Andreesen R; Rehli M
    Cancer Res; 2010 Feb; 70(4):1398-407. PubMed ID: 20145141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant DNA methylation in cancer: potential clinical interventions.
    Strathdee G; Brown R
    Expert Rev Mol Med; 2002 Mar; 4(4):1-17. PubMed ID: 14987388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of promoter CpG island hypermethylation in cancer: location, location, location!
    van Vlodrop IJ; Niessen HE; Derks S; Baldewijns MM; van Criekinge W; Herman JG; van Engeland M
    Clin Cancer Res; 2011 Jul; 17(13):4225-31. PubMed ID: 21558408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG Islands in Cancer: Heads, Tails, and Sides.
    Ferreira HJ; Esteller M
    Methods Mol Biol; 2018; 1766():49-80. PubMed ID: 29605847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting changes in methylation landscape.
    Tang L
    Nat Methods; 2019 Feb; 16(2):143. PubMed ID: 30700889
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection and interpretation of altered methylation patterns in cancer cells.
    Ushijima T
    Nat Rev Cancer; 2005 Mar; 5(3):223-31. PubMed ID: 15719030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The most frequent methods used for DNA methylation analysis].
    Chmelarová M; Palicka V
    Cas Lek Cesk; 2011; 150(8):442-5. PubMed ID: 22026079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation.
    Nguyen CT; Gonzales FA; Jones PA
    Nucleic Acids Res; 2001 Nov; 29(22):4598-606. PubMed ID: 11713309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting aberrant CpG island methylation.
    Feltus FA; Lee EK; Costello JF; Plass C; Vertino PM
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12253-8. PubMed ID: 14519846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer.
    Stirzaker C; Song JZ; Ng W; Du Q; Armstrong NJ; Locke WJ; Statham AL; French H; Pidsley R; Valdes-Mora F; Zotenko E; Clark SJ
    Oncogene; 2017 Mar; 36(10):1328-1338. PubMed ID: 27593931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DNA methylation and cancer].
    Yu L
    Zhonghua Nei Ke Za Zhi; 2005 Jun; 44(6):403-4. PubMed ID: 16008842
    [No Abstract]   [Full Text] [Related]  

  • 14. CpG islands: their potential as biomarkers for cancer.
    Shi H; Wang MX; Caldwell CW
    Expert Rev Mol Diagn; 2007 Sep; 7(5):519-31. PubMed ID: 17892361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation differences associated with tumor tissues identified by genome scanning analysis.
    Liang G; Salem CE; Yu MC; Nguyen HD; Gonzales FA; Nguyen TT; Nichols PW; Jones PA
    Genomics; 1998 Nov; 53(3):260-8. PubMed ID: 9799591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for validation and testing of DNA methylation biomarkers.
    Noehammer C; Pulverer W; Hassler MR; Hofner M; Wielscher M; Vierlinger K; Liloglou T; McCarthy D; Jensen TJ; Nygren A; Gohlke H; Trooskens G; Braspenning M; Van Criekinge W; Egger G; Weinhaeusel A
    Epigenomics; 2014; 6(6):603-22. PubMed ID: 25531255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orphan CpG islands as alternative promoters.
    Sarda S; Hannenhalli S
    Transcription; 2018; 9(3):171-176. PubMed ID: 29099304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas.
    Rønneberg JA; Tost J; Solvang HK; Alnaes GI; Johansen FE; Brendeford EM; Yakhini Z; Gut IG; Lønning PE; Børresen-Dale AL; Gabrielsen OS; Kristensen VN
    Cancer Res; 2008 Jul; 68(14):5562-71. PubMed ID: 18632608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation and gene silencing in cancer: which is the guilty party?
    Clark SJ; Melki J
    Oncogene; 2002 Aug; 21(35):5380-7. PubMed ID: 12154400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal CpG island methylation occurs during in vitro differentiation of human embryonic stem cells.
    Shen Y; Chow J; Wang Z; Fan G
    Hum Mol Genet; 2006 Sep; 15(17):2623-35. PubMed ID: 16870691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.